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Purpose of the study
Efficacy, toxicity and complexity of antiretroviral (ARV) regimens may impact the quality of life (QoL). Since over the past years
the simplification approach of lopinavir/ritonavir (LPV/r) as monotherapy (MT) has been shown to be non-inferior to triple
therapy (TT) in virological and immunological efficacy, the objective of this study was to compare several health- and treatment-
related outcomes between both ARV strategies with LPV/r.
Methods
A phase IV national, multicenter, controlled, randomized (2:1), open label, parallel-group clinical trial to compare the QoL in
patients on ARV TT containing any boosted protease inhibitor (PI), undetectable viral load (VLB 50 cop/mL) in the past 6
months and a CD4 nadir   100 cells/mL, versus those who were simplified to LPV/r MT, for 24 weeks. QoL and health outcomes
were evaluated by the Medical Outcomes Study HIV Health Survey (MOS-HIV) and the five-dimensional EuroQol questionnaire
(EQ-5D). Treatment satisfaction was assessed by the Spanish Questionnaire of Satisfaction with ARV Treatment (CESTA).
Treatment adherence was assessed by the Spanish Multifactorial Adherence questionnaire (GEEMA) and a visual analog scale
(VAS). Tolerability, safety and virological and immunological efficacy at week 24 were also analyzed.
Summary of results
225 patients from 29 sites were enrolled (MT: 146, 64.5%; TT: 79, 35.1%). Mean age (years) was 44.5 in MT and 45.2 in TT
(p0.745); mean duration (years) from HIV infection was 13.4 in MT and 12.8 in TT (p0.587) and 71% were male in both
arms. 87.6% of patients completed correctly the study (MT: 88.4%; TT: 86.1%; p0.674). Health and treatment outcomes
evaluated at final study visit are shown in figure 1. At study end, 84.1% in MT and 89.6% in TT had undetectable VL (p0.313)
and mean CD4 count were 742.8 cells/mL in MTand 646.5 cells/mLi nT T( p0.060).There were no significant differences in the
percentage of patients with virological failure at week 24 as VL  50 cop/mL (MT: 8.2%; TT: 3.9%; p0.271) and as VL  200
cop/mL (MT: 3.4%; TT: 0%; p0.167).
Conclusions
The MTsimplification strategy with LPV/r maintains comparable virological and immunological efficacy, as well as the tolerability
profile, than the TT.The saving resulting from NRTIs withdrawal from the ARV regimen and the good results on QoL and patients
treatment satisfaction make MT strategy with LPV/r be taken into account in clinical practice.
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1Figure 1. ‘Quality of life’ impact: monotherapy vs triple therapy.
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